|
US7501514B1
|
|
Enantiomeric resolution of 2-substituted 4-substituted 1,3-oxathiolanes nucleosides
|
|
WO2004096239A1
|
|
Method for administration of troxacitabine
|
|
EP1626709A1
|
|
Enantiomeric amphetamine compositions for the treatment of adhd
|
|
AU2003291882A1
|
|
Pharmaceutical combinations and methods for the treatment of leukemia
|
|
AU2003286056A1
|
|
Streptococcus pneumoniae surface polypeptides
|
|
CA2505552A1
|
|
Stereoselective process for the production of dioxolane nucleoside analogues
|
|
US2004132652A1
|
|
Pharmaceutical compositions
|
|
AU2003258422A1
|
|
Polypeptides of nontypeable haemophilus influenzae and corresponding dna fragments
|
|
AU2003246495A1
|
|
Polypeptide of streptococcus pyogenes
|
|
ZA200302823B
|
|
Dixolane analogs for improved inter-cellular delivery.
|
|
CA2475821A1
|
|
Group b streptococcus antigens
|
|
WO03062229A1
|
|
Process for producing dioxolane nucleoside analogues
|
|
US2003125305A1
|
|
Methods of treating leukemia
|
|
EP1420817A1
|
|
Moraxella (branhamella) catarrhalis polypeptides and corresponding dna fragments
|
|
BR0210875A
|
|
Group b streptococcus antigens and corresponding DNA fragments
|
|
WO02102836A2
|
|
Moraxella (branhamella) catarrhalis antigens
|
|
AU2002308325A1
|
|
Antigens of group b streptococcus and corresponding dna fragments
|
|
WO02079475A2
|
|
Streptococcus pyogenes antigens and corresponding dna fragments
|
|
AU2002242561A1
|
|
Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
|
|
MXPA03008623A
|
|
Pharmaceutical combinations for the treatment of cancer.
|
